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OBJECTIVE — To examine after gastric bypass the effect of peroral versus gastroduodenal
feeding on glucose metabolism.
RESEARCH DESIGN AND METHODS — A type 2 diabetic patient was examined on 2
consecutive days 5 weeks after gastric bypass. A standard liquid meal was given on the ﬁrst day
into the bypassed gastric remnant and on the second day perorally. Plasma glucose, insulin,
C-peptide, glucagon, incretin hormones, peptide YY, and free fatty acids were measured.
RESULTS — Peroral feeding reduced 2-h postprandial plasma glucose (7.8 vs. 11.1 mmol/l)
and incremental area under the glucose curve (iAUC) (0.33 vs. 0.49 mmol   l
1   min
1)
compared with gastroduodenal feeding. -Cell function (iAUCCpeptide/Glu) was more than two-
foldimprovedduringperoralfeeding,andtheglucagon-likepeptide(GLP)-1responseincreased
nearly ﬁvefold.
CONCLUSIONS — Improvementinpostprandialglucosemetabolismaftergastricbypassis
an immediate and direct consequence of the gastrointestinal rearrangement, associated with
exaggerated GLP-1 release and independent of changes in insulin sensitivity, weight loss, and
caloric restriction.
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R
esolution of type 2 diabetes after
Roux-en-Ygastricbypass(RYGB)has
been observed in several studies and
involves mechanisms associated with the
surgical rearrangement of the gastrointesti-
nal tract in addition to the effect of weight
loss (1). The mechanisms have not been es-
tablished, but changed gut hormone levels
after surgery may play a role (2).
Recently, we had the unique oppor-
tunity to examine the effects of feeding
either perorally (and thereby bypassing
the stomach, duodenum, and proximal
jejunum) or through a gastric tube in-
serted into the bypassed gastric remnant
on the glucose metabolism in a single
patient.
RESEARCH DESIGN AND
METHODS— A 51-year-old male pa-
tient with type 2 diabetes (BMI 50.2 kg/m
2,
A1C 8.0%) treated with metformin, sulfo-
nylurea, and insulin underwent a laparo-
scopic RYGB for morbid obesity.
On the second postoperative day, a
leakage from the gastro-jejunostomy was
suspectedbecauseoffeverandabdominal
pain. Acute reoperation showed no ﬁrm
signs of leakage, but nevertheless a per-
cutaneous gastric tube was inserted into
the bypassed gastric remnant. The tube
served as the only route of nutrition dur-
ing the following 3 weeks, after which the
patient again was allowed peroral feeding
through the gastric pouch according to a
standard nutrition protocol (1,200 kcal/
day). Treatment with insulin and met-
formin was temporarily required after the
reoperation but could be discontinued 3
weeks postoperatively.
We examined the patient 5 weeks
postoperatively, at which time the patient
was fed perorally but still had the gastric
tube. The patient had lost 14 kg (BMI
45.2 kg/m
2). Informed consent was ob-
tained prior to examination.
On 2 consecutive days at 8.30 A.M.
after an overnight fast (8 h), a standard
200-ml liquid meal (Nutridrink; Nutri-
cia) containing 300 kcal, with 16% pro-
tein,49%carbohydrate,and36%fat,was
given over a period of 10 min, on the ﬁrst
day through the gastric tube and on the
seconddayperorally.Bloodsampleswere
drawn from an antecubital vein at 15- to
30-min intervals (Fig. 1).
Laboratory analyses
Plasma glucose was measured by a glu-
cose oxidase method (ABL800Flex; Radi-
ometer, Brønshøj, Denmark), peptide
YY3–36 (PYY) with a radioimmunoassay
kit (Linco Research), and free fatty acids
(FFAs) by an enzymatic colorimetric
method (Wako, Du ¨sseldorf, Germany).
Plasma insulin, C-peptide, glucagon, and
incretin hormone were quantiﬁed as ear-
lier described (3).
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Incremental area under the curve (iAUC)
was calculated using the trapezoidal
model. -Cell function was evaluated by
iAUCinsulin, iAUCCpeptide, and insulino-
genic index (IGI) and calculated as (insu-
lin30  insulinfasting)/(Glu30  Glufasting)
and iAUCCpeptide/Glu ratio. Homeosta-
sis model assessment of insulin resis-
tance (HOMA-IR) was calculated as
(insulinfasting  Glufasting)/22.5.
RESULTS— Plasma concentrations
and iAUC for glucose, insulin, C-
peptide, glucagon, total glucagon-like
peptide-1 (GLP-1), intact glucose-
dependent insulinotropic polypeptide
(GIP), PYY, and FFAs after peroral and
gastroduodenal feeding are shown in
Fig. 1.
Plasma glucose concentration peaked
earlier and returned more rapidly to fast-
ingvaluesafterperoralthangastroduode-
nal feeding, as illustrated by a markedly
reduced 2-h plasma glucose concentra-
tion (7.8 vs. 11.1 mmol/l). iAUCGlu was
noticeably lower after peroral feeding.
The peak values of plasma insulin and C-
peptide were higher after peroral than
gastroduodenal feeding (fourfold and
twofold, respectively) and iAUCinsulin
and iAUCCpeptide were also clearly ele-
vated. IGI was improved after peroral
feeding (115 vs. 72 pmol/mmol), and the
iAUCCpeptide/Glu ratio was more than two-
fold increased (0.90 vs. 0.40 nmol/mmol).
HOMA-IR remained unchanged on the 2
examination days (3.3 vs. 3.5).
GLP-1 plasma concentration peaked
simultaneously after peroral and gas-
troduodenal feeding, but the peak value
was more than threefold increased (87 vs.
28 pmol/l), and iAUCGLP-1 was nearly
ﬁvefold increased after peroral feeding.
Insulin and GLP-1 correlated strongly af-
ter peroral (r  0.92, P  0.001) but not
gastroduodenal (r  0.55, P  0.08)
feeding. Plasma concentrations of gluca-
gon and intact GIP were similar on both
days. Responses of PYY and FFAs are de-
picted in the ﬁgure.
Figure1—Plasmaconcentrationsofglucose(A),insulin(B),C-peptide(C),glucagon(D),GLP-1(E),intactGIP(F),PYY(G),andFFAs(H)after
peroralorgastroduodenalfeedinginaRYGB-operatedpatient.FigureincludesiAUCestimations.Trianglesanddottedlines,peroralfeeding;circles
and solid lines, gastroduodenal feeding.
Improved glucose tolerance after gastric bypass
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ment in glucose tolerance after RYGB sur-
gery is a clinical reality (2). Here, we
report important differences in -cell
function and glucose metabolism after
peroral compared with gastroduodenal
feeding in a patient with RYGB and a gas-
trostomy, where differences in insulin
sensitivity, weight loss, and caloric re-
striction can be ruled out as explanations
for the improved glucose tolerance.
Our results show marked improve-
ment in glucose tolerance with near nor-
malization of 2-h postprandial plasma
glucose value and a 33% reduction in
iAUCGlu after peroral feeding compared
with gastroduodenal feeding. In contrast,
during gastroduodenal feeding glucose
tolerance was diabetic with a 2-h post-
prandial plasma glucose value 11
mmol/l. The improvement was accompa-
nied by a twofold increase in -cell secre-
tory response (AUCCpeptide/Glu), which
was associated with a ﬁvefold increase in
iAUCGLP-1. Insulin and GLP-1 concentra-
tionsduringperoralfeedingwerestrongly
correlated, which is suggestive of a causal
relationship. Interestingly, the insulin
and C-peptide response curves found af-
ter gastroduodenal feeding resemble the
responses found in type 2 diabetic pa-
tients, whereas the response curves after
peroral feeding are similar to those found
in healthy control subjects (4). The emp-
tying time is likely to be slower after feed-
ing into the bypassed gastric remnant,
which could explain the slower peak in
plasma glucose observed after gastroduo-
denal feeding but would also, per se, be
expected to result in decreased postpran-
dial glucose excursions.
The observed improvements in glu-
cose tolerance and GLP-1 secretion are in
concordance with earlier ﬁndings from
patients examined before and after RYGB
surgery (5–13). Regarding GIP, some
studies have demonstrated increased
(7,10) and others decreased (9,13) re-
sponses after RYGB. In our patient, GIP
responsesweresimilaronthe2days,sug-
gesting that changes in GIP were not re-
sponsible for the differences in insulin
secretion and glucose tolerance. Also glu-
cagon responses were similar.
Inconclusion,ourresultssuggestthat
RYGB has a direct beneﬁcial effect on
postprandial glucose metabolism, most
likely due to an increased insulin secre-
tion caused by the massive increase in
GLP-1 that is probably due to the rapid
exposure of L-cells in the distal small in-
testine to nutrients (14). It has been sug-
gested that duodenal exclusion inherent
in the RYGB somehow might be respon-
sible for the improvement in glucose tol-
erance(15).Inthisrespect,itisofinterest
thatthesecretionoftheupperjejunalhor-
mone, GIP, was similar during peroral or
gastroduodenal feeding.
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